A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.